Literature DB >> 7916917

Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.

B K Lipska1, D R Weinberger.   

Abstract

We have previously demonstrated that rats with neonatal excitotoxic hippocampal damage manifest abnormal dopamine (DA)-related behaviors after puberty, a phenomenon that has implications for an animal model of schizophrenia. In this study we investigated the effects of subchronic treatment with haloperidol and clozapine in these animals. The ventral hippocampus (VH) of rat pups was lesioned with ibotenic acid on postnatal day 7 (PD7). Starting at PD56, rats were treated for 21 days with either vehicle (VEH), haloperidol (HAL) (0.1 mg/kg, IP), or clozapine (CLOZ) (4 mg/kg, IP). Spontaneous locomotor activity was measured 0.5 hour after the last injection. Apomorphine (APO)-induced stereotypy and locomotion were evaluated five days later. The VH lesioned rats treated with VEH expressed enhanced novelty- and apomorphine-induced hyperlocomotion, as well as potentiated apomorphine-induced stereotypic behaviors as compared to sham-lesioned counterparts. Spontaneous locomotor activity was suppressed by haloperidol but not by clozapine in the sham-operated group, whereas both drugs were effective in suppressing hyperlocomotion in the VH lesioned rats. Withdrawal supersensitivity to apomorphine was seen in the haloperidol but not in the clozapine-treated lesioned rats, and none of the drugs produced significant supersensitivity in the sham-operated animals. These results indicate that the two neuroleptics exerted differential behavioral effects in neurologically intact and hippocampally lesioned animals, and that these effects were also drug-specific.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7916917     DOI: 10.1038/npp.1994.22

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  31 in total

1.  Delayed mesolimbic system alteration in a developmental animal model of schizophrenia.

Authors:  Yukiori Goto; Patricio O'Donnell
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

3.  Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia.

Authors:  Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

4.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

5.  A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus.

Authors:  Barbara K. Lipska; Daniel R. Weinberger
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

6.  Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia.

Authors:  Kuei-Yuan Tseng; Barbara L Lewis; Barbara K Lipska; Patricio O'Donnell
Journal:  Biol Psychiatry       Date:  2007-01-03       Impact factor: 13.382

7.  Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in rats.

Authors:  Susan K Conroy; Zachary Rodd; R Andrew Chambers
Journal:  Pharmacol Biochem Behav       Date:  2006-08-28       Impact factor: 3.533

Review 8.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.

Authors:  Neil M Richtand; Benjamin Taylor; Jeffrey A Welge; Rebecca Ahlbrand; Michelle M Ostrander; Jeffrey Burr; Scott Hayes; Lique M Coolen; Laurel M Pritchard; Aaron Logue; James P Herman; Robert K McNamara
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 10.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.